Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinically Relevant Drug Product Specifications: Methods of Establishment01:29

Clinically Relevant Drug Product Specifications: Methods of Establishment

105
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
105
Biopharmaceutics and Pharmacokinetics: Overview01:28

Biopharmaceutics and Pharmacokinetics: Overview

3.1K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
3.1K
Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

Biopharmaceutical Factors Influencing Drug Product Design: Overview

122
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
122
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence01:19

Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence

85
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
85
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

307
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
307
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

93
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
93

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dissolution Edge Charts for Immediate Release Products and Their Applications: a Simulation Study to Aid the Setting of Specifications.

The AAPS journal·2019
Same author

Influence of drug property and product design on in vitro-in vivo correlation of complex modified-release dosage forms.

Journal of pharmaceutical sciences·2013
Same author

In vivo bioequivalence and in vitro similarity factor (f2) for dissolution profile comparisons of extended release formulations: how and when do they match?

Pharmaceutical research·2011
Same author

Bioavailability considerations in evaluating drug-drug interactions using the population pharmacokinetic approach.

Journal of clinical pharmacology·2010
Same author

Drug-drug interaction pattern recognition.

Drugs in R&D·2010
Same author

Two commonly used methods for exposure-adverse events analysis: comparisons and evaluations.

Journal of clinical pharmacology·2009

Related Experiment Video

Updated: Dec 11, 2025

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
09:30

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

4.2K

A Biopharmetrics Approach for Drug Product Quality Control with Clinical Relevance.

John Z Duan1

  • 11120 Crestfield Dr, Rockville, MD 20850, USA.

Journal of Pharmaceutical Sciences
|August 18, 2020
PubMed
Summary

Biopharmetrics establishes clinically relevant product quality control by linking raw material attributes to in vivo exposures. This quantitative approach ensures future batches maintain bioequivalence to pivotal clinical batches.

Keywords:
BiopharmaceuticsBiopharmetricsIn vitro/in vivo correlations (IVIVC)Mathematical modelPartial least squaresProduct quality controlSimulationsSystematic approach

More Related Videos

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.4K
Purification and Analytics of a Monoclonal Antibody from Chinese Hamster Ovary Cells Using an Automated Microbioreactor System
10:50

Purification and Analytics of a Monoclonal Antibody from Chinese Hamster Ovary Cells Using an Automated Microbioreactor System

Published on: May 1, 2019

15.1K

Related Experiment Videos

Last Updated: Dec 11, 2025

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
09:30

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

4.2K
Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.4K
Purification and Analytics of a Monoclonal Antibody from Chinese Hamster Ovary Cells Using an Automated Microbioreactor System
10:50

Purification and Analytics of a Monoclonal Antibody from Chinese Hamster Ovary Cells Using an Automated Microbioreactor System

Published on: May 1, 2019

15.1K

Area of Science:

  • Pharmaceutical Sciences
  • Biopharmaceutics
  • Pharmacokinetics

Background:

  • Product quality control is crucial for ensuring clinical efficacy and safety.
  • Existing methods may lack quantitative links between raw material attributes and in vivo performance.
  • Biopharmetrics offers a systematic approach to bridge this gap.

Purpose of the Study:

  • To demonstrate a Biopharmetrics approach for product quality control with clinical relevance.
  • To establish a quantitative model connecting raw material attributes to in vivo drug exposure.
  • To define clinically meaningful specifications for raw material quality control.

Main Methods:

  • Utilized multivariate models to link raw material attributes to dissolution (Design of Experiments).
  • Extended the model to connect dissolution to in vivo exposures (AUC, Cmax) using in vitro/in vivo correlation (IVIVC).
  • Predicted exposure ratios for future batches against pivotal clinical batches to define quality control limits.

Main Results:

  • A model was established for the relationship between in vivo exposure and raw material attributes.
  • Contour lines representing exposure ratios were generated, defining lower (0.8) and upper (1.2) limits.
  • Clinically meaningful quality control specifications for raw materials were defined based on these limits.

Conclusions:

  • The Biopharmetrics approach provides a quantitative and clinically relevant method for product quality control.
  • Adherence to the defined raw material specifications ensures bioequivalence of future product batches.
  • Biopharmetrics, as a subdiscipline of biopharmaceutics, offers a framework for robust product development and control.